Active substances
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| Haemate P | 250,600 IU,IU | Powder and solvent for solution for injection/infusion · Intravenous use | 1 Vial | SAR 918.85 | Biological · Prescription | CSL | Valid |
| Haemate P | 500,1200 IU,IU | Powder and solvent for solution for injection/infusion · Intravenous use | 1 Vial | SAR 1837.70 | Biological · Prescription | CSL | Valid |
| IMMUNATE S-D 1000 I.U. POWDER FOR INJ | 1000,750 IU,IU | Powder and solvent for solution for injection · Parenteral use | 1 Vial | SAR 1138.90 | Biological · Prescription | Takeda Manufacturing AG | Valid |
| IMMUNATE S-D 250 I.U. POWDER FOR INJ | 250,190 IU,IU | Powder and solvent for solution for injection · Parenteral use | 1 Vial | SAR 331.90 | Biological · Prescription | Takeda Manufacturing AG | Valid |
| IMMUNATE S-D 500 I.U. POWDER FOR INJ | 500,375 IU,IU | Powder and solvent for solution for injection · Parenteral use | 1 Vial | SAR 663.80 | Biological · Prescription | Takeda Manufacturing AG | Valid |
| WILATE 1000 IU Powder and Solvent for Solution for Injection | 1000,1000 IU,IU | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 2738.10 | Biological · Prescription | OCTAPHARMA AG | Valid |
| WILATE 500 IU Powder and Solvent for Solution for Injection | 500,500 IU,IU | Powder and solvent for solution for injection · Intravenous use | 1 Vial | SAR 1369.05 | Biological · Prescription | OCTAPHARMA AG | Valid |
VON WILLEBRAND DISEASE, HEMOPHILIA A
Von Willebrand disease (VWD) Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A (congenital factor-VIII deficiency) Prophylaxis and treatment of bleeding in patients with haemophilia A.
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.